Table 1.
Clinical parameters of the subjects used for HBV sequencing
| whole HBV sequencing | |||
|---|---|---|---|
| HCC group 1 | non-HCC group 1 | ||
| (n = 37) | (n = 38) | ||
| Age (Years) | 37 ± 10.0 | 38 ± 11.6 | |
| Sex:Male | 29 (78%) | 28 (73%) | |
| HBV-DNA (log/ml) | 5.5 ± 1.1 | 5.2 ± 0.9 | |
| HBeAg positive | 20 (54%) | 20 (52%) | |
| Platelet (× 104/μl) | 11.4 ± 5.3 | 16.4 ± 6.0 | |
| Total Bilirubin (mg/dl) | 1.3 ± 1.1 | 1.6 ± 1.97 | |
| Albumin (g/dl) | 3.58 ± 0.8 | 4.0 ± 0.44 | |
| core promoter sequencing | |||
| HCC group 2 | non-HCC group 2 | pre-HCC group 2 | |
| (n = 40) | (n = 52) | (n = 16) | |
| Age (Years) | 54 ± 13.1 | 38 ± 11.4*# | 48 ± 10.2 |
| Sex:Male | 78% | 83% | 94% * |
| HBV-DNA (log/ml) | 5.76 ± 2.04 | 7.23 ± 1.37* | 6.42 ± 1.66 |
| HBeAg positive | 55% | 75% | 79% |
| Platelet (× 104/μl) | 12.1 ± 6.39 | 17.1 ± 7.15* | 15.0 ± 6.59 |
| Total Bilirubin (mg/dl) | 1.32 ± 1.13 | 1.29 ± 2.07 | 2.55 ± 6.66 |
| Albumin (g/dl) | 3.58 ± 0.84 | 4.10 ± 0.51* | 3.84 ± 0.57 |
*p < 0.05 vs. HCC group 2, #p < 0.05 vs. pre-HCC group 2